Rx Labeling Should Be Left To Manufacturers, Not FDA, Pfizer Says
Executive Summary
FDA should allow manufacturers to choose the exact wording of required substantive information in their labels, 1Pfizer's comments on First Amendment issues state
You may also be interested in...
Duloxetine’s Dual Names: Lilly Wants Yentreve As Incontinence Brand
Lilly is asking FDA to accept Yentreve as the trade name for duloxetine for the treatment of stress urinary incontinence
Duloxetine’s Dual Names: Lilly Wants Yentreve As Incontinence Brand
Lilly is asking FDA to accept Yentreve as the trade name for duloxetine for the treatment of stress urinary incontinence
Pfizer Asks Supreme Court To Protect “Right Of Reply” In Cases Like ALLHAT
The ALLHAT study report illustrates why manufacturers need a clearly articulated "right of reply" under the First Amendment, Pfizer told the Supreme Court in an amicus curiae brief filed in support of Nike's appeal of Kasky v. Nike